Fatima Laher to Vaccination
This is a "connection" page, showing publications Fatima Laher has written about Vaccination.
Connection Strength
0,345
-
Review of preventative HIV vaccine clinical trials in South Africa. Arch Virol. 2020 Nov; 165(11):2439-2452.
Score: 0,150
-
Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Sci Rep. 2020 08 03; 10(1):13031.
Score: 0,037
-
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
Score: 0,037
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0,035
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0,032
-
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016 04; 17:104-109.
Score: 0,028
-
A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine. 2015 Jun 09; 33(25):2944-54.
Score: 0,026